ArticleScientific reports2025
AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Technologies for Monoclonal Antibody Discovery and Development.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we developed a digital twin for SARS-CoV-2 by integrating diverse data and metadata with multiple data types and processing strategies, including machine learning, natural language processing, protein structural modeling, and protein sequence language modeling. This approach enabled us to computationally design neutralizing antibodies against over 1300 historical strains of SARS-CoV-2, encompassing 64 mutations in the receptor binding domain (RBD) region. 70 AI-designed antibodies were experimentally validated through binding assay and real viral neutralization assays against various strains, including later Omicron strains do not present in the initial design database. 14% of these antibodies exhibited strong reactivity against the RBD of multiple strains, achieving triple cross-binding hit rates using ELISA assay. 10 antibodies neutralized the cytopathic effects (CPE) of the Delta strain at IC50 values of < 10 µg/ml, and one antibody neutralized the CPE of Omicron. These findings demonstrate the potential of our approach to influence future therapeutic design for existing virus strains and predict hidden patterns in viral evolution that AI can leverage to develop emerging antiviral treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.